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Abstract: With advances in breast cancer (BC) gene panel testing, risk counseling has become
increasingly complex, potentially leading to unmet psychosocial needs. We assessed psychosocial
needs and correlates in women initiating testing for high genetic BC risk in clinics in France
and Germany, and compared these results with data from a literature review. Among the
442 counselees consecutively approached, 212 (83%) in France and 180 (97%) in Germany, mostly BC
patients (81% and 92%, respectively), returned the ‘Psychosocial Assessment in Hereditary Cancer’
questionnaire. Based on the Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation
Algorithm (BOADICEA) BC risk estimation model, the mean BC lifetime risk estimates were 19%
and 18% in France and Germany, respectively. In both countries, the most prevalent needs clustered
around the “living with cancer” and “children-related issues” domains. In multivariate analyses,
a higher number of psychosocial needs were significantly associated with younger age (b = −0.05),
higher anxiety (b = 0.78), and having children (b = 1.51), but not with country, educational level,
marital status, depression, or loss of a family member due to hereditary cancer. These results are in line
with the literature review data. However, this review identified only seven studies that quantitatively
addressed psychosocial needs in the BC genetic counseling setting. Current data lack understandings
of how cancer risk counseling affects psychosocial needs, and improves patient-centered care in
that setting.
Keywords: breast cancer; genetic risk; risk counseling; psychosocial needs; distress; service delivery;
culture
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1. Introduction
Breast cancer (BC) is a major public health concern for women, with almost 1.7 million new BC
diagnoses worldwide in 2012 [1]. Among these BC patients, 10% to 20% present with a BC family
history, and two decades ago, BRCA1 and BRCA2 were identified as major BC susceptibility genes [2].
Women who carry a mutation in the BRCA1 or BRCA2 gene face up to a 72% and 44% risk of developing
breast or ovarian cancer, respectively, by the age of 80 [3]. When already affected with BC, these women
present an increased risk of contralateral BC [3].
The identification of a pathogenic variant in highly penetrant genes such as BRCA1 or
BRCA2 provides options for early detection or prevention. There is evidence that a risk-reducing
bilateral mastectomy decreases the risk of BC by 85% to 100% [4], and that risk-reducing bilateral
salpingo-oophorectomy reduces the risk of ovarian cancer by 69% to 100%, and the risk of BC by 37%
to 100% [4]. When a pathogenic variant is identified, genetic testing may be offered to relatives.
Recently, additional genetic factors have been identified, including rare variants with “moderate”
(CHEK2, ATM, BARD1 and RAD51D) to “high” (PALB2) BC risk [5]. Thanks to technological advances,
instead of testing the BRCA1 and BRCA2 genes alone, panels of genes may now be simultaneously
tested, at a reduced cost and faster turnaround [6]. As a result, over the past few years, these tests have
entered oncologic genetic clinics [7–9].
National guidelines recommend the inclusion of cancer genetic testing within a framework
of genetic counseling [10]. This healthcare discipline is defined as “the process of helping people
understand and adapt to the medical, psychological, and familial implications of genetic contributions
to disease” [11]. Among tasks such as cancer risk assessment, informed consent collection,
the disclosure of genetic test results, and medical recommendations, genetic counseling comprises
psychosocial assessment [12]. Thus, the relevance of a ‘patient-centered care approach’ addressing
psychosocial needs in this clinical setting should be underlined.
Psychosocial needs refer to psychological and social difficulties, and the type and extent of help
a patient actually needs or expects in order to manage these difficulties [13]. Potential needs in
cancer genetics may be motivated by specific issues related to the cancer genetic risk, counseling,
and testing [14], and may request additional help from a clinical geneticist, genetic counselor,
gynecologist, breast surgeon, or psychosocial worker. In past decades, there has been increased
interest in needs assessment in cancer care [15], and in cancer genetics; specific questionnaires have
been developed in order to address these concerns and adjust cancer care as necessary [16,17].
Genetic counseling confronts large quantities of information involving statistic and genetic
concepts, which are generally imprecise and complex, and are sources of uncertainty [18]. Moreover,
genetic counselors tend to communicate unidirectionally, providing large pieces of information, and at
the same time often neglecting to enquire about counselees’ needs [19], leaving them with potentially
unfulfilled needs after the consultation [20,21].
In the gene panel testing environment, genetic counseling is further complicated, as information
must be provided on possible new quantitative results (i.e., “moderate” cancer risk with unwell
defined guidance for clinical management [22]), an increased number of variants of uncertain
clinical significance (VUS) [23], or the possibility of secondary or incidental results [24]. In addition,
the involvement of non-genetic factors in BC risk [25] further complicates counseling.
Assessing psychosocial needs during the care trajectory allows for clarifying what type of
interventions (i.e., depending on specific needs) or for which population (i.e., depending on its
characteristics) the provision of specific health care resources is necessary [26]. Variations across
countries in the BC genetic risk counseling process exist, e.g., in terms of risk communication [27]
or clinical recommendation [22]. Patterns of psychosocial needs are expected to vary according to
these variations.
Psychosocial needs may also reveal based on counselees’ sociodemographic, family history,
and clinical or psychosocial characteristics. If their psychosocial needs are similar across counselees’
characteristics, but are different across countries, this implies that the mode of counseling delivery
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is associated with needs, and this may have implications for clinical practice according to specific
settings [28].
To our knowledge, only two United States (US) studies [29,30] reported on psychosocial outcomes
in women at high genetic risk of BC undergoing gene panel testing. Initial (pretest) genetic counseling
generally provides information allowing counselees to make informed decisions regarding testing and
the receipt of genetic information. The present study addressed the psychosocial needs of women at a
high genetic risk of BC undergoing genetic counseling in French and German cancer genetic clinics in
order to highlight possible unmet care needs before actual genetic panel testing.
Specifically, we aimed to:
(1) Assess the prevalence of moderate and high psychosocial needs in women undergoing genetic
counseling and testing for BC risk in a French and a German cancer genetic clinic, and compare
them between the two countries;
(2) Explore sociodemographic, clinical, psychological, and geographical (i.e., the country setting)
factors associated with the number of moderate and high psychosocial needs in these women; and
(3) Compare these results with empirical data extracted from a literature review addressing the
domains and specific items of psychosocial needs that are most frequently reported along the
cancer genetic counseling and testing process.
2. Materials and Methods
This study protocol was approved in France by the Comité consultatif sur le traitement de
l’information en matière de recherche dans le domaine de la santé (CCTIRS: Consultative committee for
information management in health research—No. 16.314, France), and by the Commission Nationale
Informatique et Libertés (CNIL: French Information Technology and Privacy Commission), and in
Germany by the Ethics Committee of the University Hospital of Cologne. All of the recruited women
provided written informed consent.
2.1. Participants and Procedure
From October 2016 to July 2017, women over the age of 18 years, who were either healthy or
affected with a primary non-metastatic breast cancer, and eligible for BC gene panel testing, were
consecutively recruited at the cancer genetic units of the Institut Curie (Paris, France) and the University
Hospital of Cologne (Cologne, Germany). A minimum sample size of 200 was required to allow for
comparisons between the two country cancer genetic services. Women with a recurrent BC, a personal
history of ovarian cancer, or a major psychiatric disorder were not included.
The study objectives were explained to the women on the day of the initial cancer genetic
counseling visit, and when they agreed to participate, they were given questionnaires to fill in at home,
either in paper or online, and to return within the next two weeks. Questionnaires not completed or
received within 28 days after the genetics consultation were considered missing. If necessary, 14 days
after the consultation, one reminder was made by telephone call.
2.2. Questionnaire and Data Collected
2.2.1. Psychosocial Outcome
The ‘Psychosocial Aspects of Hereditary Cancer’ (PAHC) questionnaire is comprised of 26 items
organized into six problem domains, i.e., needs related to hereditary predisposition, practical issues,
family and social issues, living with cancer, emotions, and children-related issues [17]. Participants are
asked to rate each question on a scale from “not at all” (1), “a little” (2), “quite a bit” (3), or “a lot” (4).
A “not applicable” option is provided to some items (e.g., items regarding children-related issues).
The PAHC items were translated and adapted into French and German according to international
guidelines [31], and were pilot tested in the respective country’s cancer genetic clinic. The internal
consistency of the overall PAHC 26-item scale was 0.87.
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2.2.2. Independent Variables
General distress (i.e., anxiety and depression) was measured by the Hospital Anxiety and
Depression Scale. This scale comprises anxiety (HADS-Anxiety) and depression (HADS-Depression)
subscales, and has French [32] and German [33] versions.
Women were also asked if they had lost family member(s) due to breast or ovarian cancer.
To compute the objective risk estimates of breast and of ovarian cancer up to the age of 80 years,
the Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm (BOADICEA)
web application (BWA v3, University of Cambridge, Cambridge, UK) [34] was used.
Additional data were collected on the sociodemographic characteristics provided by the patient,
and the clinical data obtained from the medical record.
2.3. Statistical Analysis
Baseline sociodemographic and clinical characteristics of the participants were described using the
mean (standard deviation) or median (range) for continuous variables, and the number (percentage)
for qualitative variables. We used the Student t-test for quantitative data and the Chi-square test for
categorical data to compare study participants among the French and the German respondents, and
between the age of overall respondents and non-respondents. Response frequencies were computed
for each PAHC item. We computed the frequency (percent) of individuals reporting moderate to high
needs (at least “quite a bit” responses) per item. A Chi-square test was performed to compare the
percentage of patients with a moderate to high need per item between the two countries.
Multivariate regression analyses were performed on the number of needs (rated at least “quite a
bit”) per individual, as a dependent variable. Psychosocial needs were taken as a whole, considering
that the PAHC structural validity was not yet confirmed in these PAHC language versions (work in
process). The country sample, age, educational level (secondary school or below versus superior
education), marital status (married or partnered versus single, separated, divorced or widowed),
parental status (having children or not), HADS-anxiety and HADS-depression scores (continuous
variables), health status (affected or not with a present or past BC diagnosis), and family history (having
lost a blood family member from breast or ovarian cancer) were assessed as potential predictors in
univariate analyses. The collinearity between variables was tested in univariate analysis; variables
presenting collinearity were not simultaneously included in the same multivariate model. A stepwise
selection approach was then used to select the final multivariate model.
2.4. Literature Review Procedures
A systematic search of the PubMed/Medline database was conducted. We selected papers
published between January 2000 (before that time, BRCA1/2 psychosocial outcomes were mainly
addressed on researched cohorts rather than in “real” clinical practice [35]) to 17 October 2017
(last check), assessing the overall psychosocial difficulties or needs of women who had a high
breast or ovarian cancer genetic risk, and considering only observational quantitative studies, using
genetics-specific, multidimensional measures (keyword combinations, see Supplementary Materials
Table S1).
All of the titles and abstracts were inspected for relevance, excluding papers such as protocol
descriptions, literature reviews, studies addressing the period of referral or following cancer risk
management decision-making, men only, healthcare professionals, genetic testing for breast or ovarian
treatment decision-making, or controlled (randomized) trials. Thirteen papers were rejected on full text
as they only addressed a specific outcome (e.g., general or specific distress, quality of care perception)
(11 papers) or generic difficulties/needs measures such as the SF-36 (two papers). The two remaining
papers [36,37] were analyzed in addition to five studies identified from a manual search [30,38–41],
for a total of seven inspected studies.
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Two authors (Anne Brédart and Jean-Luc Kop) extracted the study descriptive data (study country,
sample size, response rate, study population age and gender, timing of assessment, type of cancer
genetic risk, cancer diagnosis status, and psychosocial need measure; see Supplementary Materials
Table S2), and the prevalence of needs (the number of patients that expressed individual need items),
and identified significant relationships between the various factors and psychosocial needs within each
study. Additionally, the psychosocial needs measured were described based on the original publication
(which measured the aim and targeted population, number of items, scales/domains, developmental
and psychometric information, and scoring method; see Supplementary Materials Table S3).
3. Results
3.1. Samples’ Characteristics
Table 1 displays the characteristics of the French and German samples. Among the 442 counselees
approached, 212 (83%) in France and 180 (97%) in Germany provided evaluable PAHC responses.
The French and German respondents had a mean age (standard deviation) of 47.8 (12.0) and
47.7 (10.2) years, and 171 (81%) and 165 (92%) were affected with BC, respectively. These women
were either under treatment or in remission. The mean (standard deviation) levels of anxiety and
depression were 7.94 (3.82%) and 3.81 (3.03%) and, 7.52 (4.07%) and 4.61 (3.96%) respectively, in the
French and German samples. Based on the BOADICEA BC risk estimation model [34], the mean
(standard deviation) percent of BC lifetime risk estimates by age 80 was 19.2 (11.6%) and 18.0 (9.1%) in
France and Germany, respectively.
Table 1. Sociodemographic and clinical characteristics of the two samples.
French Respondents
(N = 212)
German Respondents
(N = 180) p-Value
Age (years)
Mean (SD) 47.8 (12.0) 47.7 (10.2) NS
Median (range) 48 (21–78) 48.5 (23–74)
Education level (%)
Secondary school or below 66 (31.1) 127 (70.6) <0.0001
Superior education 144 (67.9) 51 (28.3)
Missing data 2 (0.94) 2 (1.11)
Marital status (%)
Married/partnered 148 (69.8) 120 (66.7) NS
Others (widowed, separated/divorced, single/never married) 63 (29.7) 59 (32.8)
Missing data 1 (0.47) 1 (0.56)
Having children (%) (Yes) 168 (79.3) 128 (71.1) 0.06
Missing data
Personal breast cancer (%) (Yes) 171 (80.7) 165 (91.7) 0.001
Missing data 0 (0) 1 (0.01)
Breast cancer lifetime risk
BOADICEA estimates
Mean (SD) 19.2 (11.6) 18.0 (9.1) NS
Median (range) 17.5 (0.8–82.9) 16.5 (1.5–81.1)
HADS-Anxiety
Mean (SD) 7.94 (3.82) 7.52 (4.07) NS
Median (range) 8 (1–19) 7 (0–19)
Missing data 9 2
HADS-Depression
Mean (SD) 3.81 (3.03) 4.61 (3.96) 0.03
Median (range) 3 (0–14) 3 (0–20)
Missing data 6 3
NS: not statistically significant; BOADICEA Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation
Algorithm; HADS: Hospital Anxiety and Depression Scale; SD: standard deviation.
Overall respondents’ and non-respondents’ mean (standard deviation) age was 47.8 (11.2) and
45.5 (11.9), respectively (the difference was not statistically significant). Compared to the German
respondents, the French respondents were significantly less often affected with BC (p = 0.001),
and presented a higher level of education (p < 0.0001) and a lower depression level (p = 0.03).
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3.2. Prevalence of Moderate to High Psychosocial Needs
Out of the over 26 potential psychosocial needs assessed with the PAHC, seven needs were
reported by more than 50% of the French women, and five needs were reported by more than 50% of
the German women (% prevalence of women rating the presence of each need at least “quite a bit”)
(Table 2). Among the 10 most prevalent needs, five clustered around the “living with cancer” domain in
the French and German samples, two around “children-related issues”, two around “family and social
issues”, and one around “hereditary predisposition” in the French sample; and two around “emotion”,
two around “hereditary predisposition”, and one around “children-related issues” in the German
sample. Nine needs were reported as significantly more severe by women from France than Germany,
whereas two needs were reported as significantly more severe by women from Germany than France.
The mean (standard deviation) number of needs were 7.5 (5.3%) and 6.3 (5.3%), respectively, in the
French and German samples, which was significantly different (p < 0.01).
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Table 2. Prevalence of participant’s responses to the Psychosocial Aspects of Hereditary Cancer (PAHC) items (% rated at least quite a bit) in the French and German
study samples.
Prevalence of Needs TOTAL (N = 392) French Sample (N = 212) German Sample (N = 180)
PAHC items $ % rated at least quite a bit % %
Worried about the chance of being a carrier of a genetic mutation (HP) 41 40 43
Worried about having to choose whether or not to go for genetic counseling and testing (HP) 6 4 8
Worried about the choice of possible preventive options (screening or surgery) (HP) * 27 22 33
Worried about coping with the (future) DNA test results (HP) 26 24 29
Worried about (fulfilling) your plans for having children (HP) ** 11 16 6
Worried about the impact of genetic testing on your daily life (PI) 20 21 18
Worried about the impact of genetic testing on obtaining insurance or mortgage (PI) **** 18 27 9
Misunderstood by partner/family/social circle with respect to genetic testing (FSI) 3 3 3
Bothered by lack of support about genetic testing from partner, family, or your social circle (FSI) 3 4 2
Worried about immediate family’s functioning because of genetic testing (FSI) * 12 8 16
Worried about the contact with family members about genetic testing (FSI) ** 6 10 3
Worried about coping with cancer within the family (FSI) **** 43 61 25
Burdened by feelings of responsibility towards family members related to genetic testing (FSI) **** 30 40 20
Anxious (E) * 22 26 18
Tense (E) 24 21 28
Depressed (E) 11 8 13
Insecure about the future (E) 31 27 35
Concerned about life and death (E) 33 31 35
Emotionally burdened that family members have cancer (LWC) **** 54 71 36
Emotionally burdened by losing a family member because of cancer (LWC) 80 83 77
Emotionally burdened by the diagnosis or treatment for cancer (LWC) 56 52 61
Worried about the chance of getting cancer (again) (LWC) 64 66 62
Worried about the chance that family members will get cancer (LWC) 69 72 65
Guilty about the chance of passing possible genetic alterations onto children (CRI) **** 30 39 20
Worried about telling children the results (CRI) 27 28 26
Worried about the chance of children developing cancer (CRI) * 72 79 65
Number of needs **
Mean (SD)
Median (Min–Max)
7.84 (5.00)
7 (0–24)
7.54 (5.31)
7 (0–24)
6.27 (5.28)
5 (0–20)
$ Living with cancer (LWC), Family/Social issues (FSI), Children-related issues (CRI), Hereditary predisposition (HP), Emotion (E), Practical issues (PI); * p-value < 0.05, ** p-value < 0.01,
*** p-value < 0.001, **** p-value < 0.0001.
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3.3. Correlates of Psychosocial Needs
In multivariate analyses, a significantly higher number of needs was observed in younger women
(b = −0.05; p = 0.01), as well as in those with a higher level of anxiety (b = 0.78; p < 0.0001) and those
with children (b = 1.51; p = 0.002) (Table 3). A trend towards a higher number of needs was also observed
in women affected with BC (b = 1.05; p = 0.08). The sample country, marital status, education level,
depression level, and loss of family members due to breast or ovarian cancer showed no statistically
significant association. The variance in the number of needs explained by the regression model was 40%.
Table 3. Multiple regression results of factors associated with the number of psychosocial needs.
Factors Categories
Univariate Models
(N = 392)
Final Multivariate Model
(N = 380)
b SE p Value b SE p Value
Intercept 4.53 1.08 <0.0001
Country Germany (vs. France) −1.29 0.5 0.01 - -
Age −0.04 0.03 NS −0.05 0.02 0.01
Education level Secondary school or below −0.39 0.51 NS - -
Marital status Others (than married/partnered) 0.16 0.54 NS - -
Breast cancer diagnosis Yes −0.05 0.73 NS 1.05 0.60 0.08
HADS-Anxiety 0.79 0.05 <0.0001 0.78 0.05 <0.0001
HADS-Depression 0.6 0.07 <0.0001 - -
Loss of family member No 0.43 0.58 NS - -
Having children Yes −1.45 0.58 0.01 1.51 0.48 0.002
R2 (% of explained variance) 0.40
NS: non-statistically significant; HADS: Hospital Anxiety and Depression Scale
3.4. Description of Studies from the Literature Review
The seven studies available were from different Western countries (Australia [36], Austria [37],
Netherlands [40], Norway [39], the United Kingdom (UK) [38], and the US [30,41]) (Supplementary
Materials S2). With one exception [38], studies were cross-sectional. Five studies addressed breast
or ovarian cancer genetic risk [30,36,37,39,41], and the two others reported on various hereditary
syndromes [38,40]. Five studies comprised samples with 50% or more counselees affected with
cancer [30,37,39–41]. Four studies [30,37,39,41] used the ‘Multidimensional Impact of Cancer Risk
Assessment’ (MICRA) to assess counselees’ psychosocial difficulties [16], and the three others
specifically used the ‘Genetic Risk Assessment Coping Evaluation’ (GRACE) [38,42], the ‘Psychosocial
Assessment in Hereditary Cancer’ (PAHC) [17,40], or a modified version of a psychosocial needs
questionnaire for BC survivors [36]. Among these questionnaires, only the MICRA provided information
on scale validity (structure) and reliability (internal consistency) [16] (Supplementary Materials S3).
3.5. Prevalence of Needs from the Literature Review
Table 4 describes the psychosocial needs, as expressed at the initial cancer genetic consultation one
month later, or in the medium or long-term after the genetic test result disclosure, depending on the
study. At the initial consultation and in counselees from various hereditary cancer syndromes, using
the PAHC [17], the most prevalent needs were clustering around “living with cancer” [40], and using
the GRACE [42], these were related to family, hereditary predisposition, or practical issues, over two
assessment times one month apart [38].
After the disclosure of the BRCA1/2 test result, using the MICRA questionnaire [16],
BjØrnslett et al. [39] reported a higher level and a different hierarchy of needs prevalence in BRCA1/2
carriers compared to non-carriers (e.g., “frustrated that there are no definite cancer prevention
guidelines for me”; 41%/ninth highest prevalent need, versus 38%/third highest prevalent need).
Around two years after the BRCA1/2 test disclosure, Farrelly et al. [36] found that 50% of women or
more presented needs in the three issues: “fear of developing cancer”, “family communication”, and
“information on cancer risk management options”. Finally, at around seven years, after the BRCA1/2
test disclosure, using the MICRA scales [16], uncertainty appeared to be the most prevalent need,
as expressed by 59% of BRCA1/2 tested women, whatever the BRCA1/2 test result [41].
Int. J. Environ. Res. Public Health 2018, 15, 319 9 of 16
Table 4. Literature review—Prevalence of needs.
Measure % Prevalence
PAHC
% Rated above threshold of ≥3/domain ([40], Netherlands, various hereditary cancer syndromes) Initial consultation
Living with cancer (LWC) 84
Hereditary predisposition (HP) 46
Family/social issues (FSI) 45
Children-related issues (CRI) 42
Emotions (E) 29
Practical issues (PI) 19
GRACE *
% Rated at least quite a bit ([38], UK, partly HBOC) Initial consultation (Female) 1 month later/before test result disclosure (Female)
Implications of being at “increased” risk for cancer for other family members (FSI) 73 59
How one’s family would react if found to have an increased risk for cancer (FSI) 72 58
Will cope if found to have an increased risk of cancer (HP) 67 53
Possible future decisions about surgery(HP) 55 40
Impact of being at “increased” risk of cancer on lifestyle (PI) 50 44
Being able to get increased screening (HP) 49 27
Having to wait for information about one’s risk (HP) 47 39
Asking family members about family history (FSI) 41 35
Whether would be eligible for genetic testing (HP) 37 28
Completing the family history questionnaire (HP) 36 31
Not understanding the risk assessment process (HP) 24 19
MICRA
% Rated at least sometimes ([39], Norway, ovarian cancer) BRCA1/2 carriers Non-carrier affected/not and/or with/without family history
Negative items
Worrying about my risk of getting cancer (again) 84 69
Uncertain about what the test result means for child(ren)/family’s cancer risk 84 43
Sad about my test result 69 5
Uncertain about what my test result means about my cancer risk 59 37
Anxious or nervous about my test result 50 8
Feeling a loss of control 50 8
Thinking that the test results have affected my work or family life 44 15
Upset about my test result 41 7
Frustrated that there are no definite cancer prevention guidelines for me 41 38
Guilty about my test result 31 2
Concerned about how my test results will affect my insurance status 31 10
Problems enjoying life because of my test result 25 6
Difficulty talking about my test results with family members 19 7
Difficulty making decisions about cancer screening or prevention (e.g., having preventive surgery or getting medical tests done) 18 14
Worrying that genetic counseling and testing process brought about conflict within my family 16 3
Regret about getting my test results 9 1
Positive items
Happy about my test result 12 83
Relieved about my test result 16 82
Understanding clearly my choices for cancer prevention/early detection 84 68
Satisfied with family communication about my genetic test result 84 82
Feeling that family has been supportive during the genetic counseling and testing process 90 79
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Table 4. Cont.
Measure % Prevalence
SUPPORT NEEDS *
% Rated high to very high ([36], Australia, BRCA1/2 tested) ≈1.7 years post test result
Dealing with fears about developing cancer (LWC) 57
Talking to other family members about having a faulty cancer protection gene (FSI) 54
Obtaining information about the different options available to help manage your increased risk for cancer (HP) 51
Dealing with uncertainty about the future (E) 49
Talking to your children about their cancer risk (of women with children, n = 224) (CRI) 48
Deciding how best to manage your increased cancer risk (HP) 43
Talking with other women who have a faulty cancer protection gene (FSI) 41
Finding someone who understands your situation (FSI) 39
Dealing with feelings of sadness (E) 38
Dealing with the impact that having a faulty gene has had on your family (FSI) 37
Reassurance that the way you feel about your risk is normal (E) 35
Dealing with the loss of family members who had breast cancer (FSI) 34
Obtaining more information about the level of risk for breast cancer (HP) 32
Understanding the information you have been given about your cancer risk (HP) 32
Dealing with insurance issues that arise from having a faulty cancer protection gene (PI) 23
Dealing with feelings of isolation (E) 22
MICRA
% Rated at least rarely per domain ** ([41], USA, BRCA1/2 tested) ≈7 years post test result
Distress 26
Uncertainty 59
Positive experience 51
* Items classified according to Eijzenga et al. [17] needs’ categorization; ** Distress & Uncertainty: scores > 0; Positive experience: scores <20; PAHC: psychosocial aspects of hereditary
cancer; GRACE: Genetic Risk Assessment Coping Evaluation; MICRA: Multidimensional Impact of Cancer Risk Assessment; HBOC: Hereditary Breast and Ovarian Cancer ; BRCA1/2genes.
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3.6. Correlates of Needs from the Literature Review
A significant increase in needs was found in younger counselees [36], women with children [40],
carriers of a deleterious mutation [30,37,39,41], and those who had received a VUS test result [30];
further correlates were a shorter time since the initial counseling [38] or genetic test disclosure [36,41],
distress [39,40], previous contact with a psychosocial worker [40], and lower social support [36].
A number of tested factors, including demographics [39,41], clinical characteristics [36,37,39–41],
family history [36,39], and assessment timing [39], were not significantly associated with needs.
Aspects of the cancer genetic counseling delivery (e.g., psychosocial assessment, risk communication,
or counseling) in relation to psychosocial needs were not investigated in the selected reviewed studies
(Table 5).
Table 5. Literature review: correlates of concerns, difficulties, needs, care preferences, and unmet needs.
Study Needs Correlates
Variables Effect Sizes (Multivariate Results *)
Bennett [38]
(N = 194) Assessment timing
Level of GRACE concerns fell over time for “implications for family
members if at increased risk” (Cohen’s h = 0.30); “how family would
react if at increased risk” (Cohen’s h = 0.26); “possible decisions about
surgery” (Cohen’s h = 0.28); “being able to get increased screening”
(Cohen’s h = 0.38); and “having to wait to find out risk” (Cohen’s
h = 0.16)
Bjornslett [39]
(N = 354)
Age, education, having
children, clinical, family
history, test result, breast/
ovarian cancer, assessment
timing, distress
Being a mutation carrier (β = 0.40) and higher traumatic anxiety
(β = 0.48) related to the MICRA total score
Eijzenga [40]
(N = 137)
Age, education level, marital
status, having children, gender,
clinical, index case, mutation
in family, anxiety/depression,
previous contact with
psychosocial worker
Having children associated with hereditary predispositions (OR = 2.56)
and family/social issues (OR = 3.56); previous contact with psy
associated to practical issues (OR = 0.38); anxiety/depression associated
to higher all-domain needs, but partial correlations only significant for
general emotions (rp = 0.49), and family and social issues (rp = 0.19)
Farrelly [36]
(N = 279)
Age, education, marital status,
having children, clinical,
family history, assessment
timing, someone to confide in
Age (β = −0.11), having a significant other to confide in (β = 0.14); time
since notification of mutation status (β = −0.17) related to higher total
need scores
Halbert [41]
(N = 167) Age, clinical, test result, timing
BRCA1/2 carriers have more distress (OR = 3.96); shorter time since test
disclosure related to more uncertainty (OR = 0.62)
Lumish [30]
(N = 232)
Age, race, education, clinical,
test result, assessment timing,
genetics knowledge (only
clinical and test results tested)
MICRA total scores were greater in the “no CA/mutation +” group.
MICRA distress scores were greater in the “no CA/mutation +” group
than in any of the other groups; the “CA/VUS” group had a higher
MICRA distress scores than all of the other groups, other than the “no
CA/mutation +” group. The “no CA/VUS” and the “CA/mutation +”
groups had worse positive experience scores **
Oberguggenberger [37]
(N = 137)
Breast/ovarian cancer
diagnosis, test results
Significant difference in MICRA scales between positive versus
negative results: distress: Cohen’s d = 0.57; uncertainty: Cohen’s
d = 0.51; positive experiences: Cohen’s d = 0.96
* When available, only multivariate results were provided; ** Effect size could not be computed. GRACE: Genetic
Risk Assessment Coping Evaluation; OR: odds ratio; VUS: variants of uncertain clinical significance.
4. Discussion
This study primarily aimed to assess the prevalence of psychosocial needs in women initiating
genetic counseling for high BC risk in a French and a German cancer genetic clinic, and explore
correlates of increased needs, including the country setting. We compared these results to data extracted
from a literature review in order to shed light on implications for research and clinical applications.
A substantial proportion of women in both countries perceived significant difficulties in the
“living with cancer” domain, which referred to living with both actual cancer as well as the threat of
personal or familial cancer diagnoses. In addition, they also experienced concerns in the “family and
social issues” domain, representing the interpersonal aspects of the cancer genetic risk. Interventions
should thus focus on these particular difficulties in both institutions. Besides, independently from
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the country, the overall number of needs was found to be higher in younger women, in those having
children, or those presenting increased anxiety; therefore, attention should be given to the needs of
these women in particular.
Specific differences were also observed between the two country samples. For instance, compared
to the German sample, a higher proportion in the French sample worried about children-related issues.
For example, women attending the French cancer genetic clinic more frequently expressed “guilt
about the chance of passing on genetic alterations to their children” than the German sample; this may
suggest that women in the French genetic clinic may need additional counseling for dealing with
this feeling of guilt. In contrast, women attending the German cancer genetic clinic more frequently
expressed preoccupations related to the hereditary predisposition, such as “worries about the choice
of possible preventive options (screening versus surgery)”, which points to the need for additional
support in decision-making with regard to management options in the German clinic.
Significant differences (i.e., education level, BC status) between the two country samples may
require specific clinical implications by clinic setting. As only the actual BC diagnosis status appeared
to be (to some extent) related to a higher number of needs, interventions should predominantly
emphasize the needs of women affected with BC.
Our results are in line with the information obtained from the literature review, confirming a high
prevalence of psychosocial needs following genetic counseling, including aspects in relation to the
cancer diagnosis [40] or family and social issues [38] after the initial cancer genetic consultation.
Other reviewed studies investigated the prevalence of these needs over time, showing that these
needs may remain high (above 50%), independent of the genetic test result: 59% of women worried
about the “implications of being at increased risk of cancer for other family members” one month after
the initial genetic consultation [38]; 84% of BRCA1/2 carriers and 69% of non-carriers “worried about
their risk of getting cancer/again” [39]; 57% of BRCA1/2 carriers “dealt with fears about developing
cancer” at about two years after the genetic test result disclosure [36]; and 59% felt confronted
with “uncertainty” about seven years after receiving the genetic test result [41]. This underlines the
importance of monitoring psychosocial needs over a longer period of time in individuals confronted
with BC genetic risk.
The literature review data found that younger age [36], having children [40], and anxiety [39,40]
correlated with psychological needs, thus supporting our findings. To gain further insights into the
psychosocial needs of women along the process of BC gene panel testing, we are currently planning a
follow-up assessment on psychosocial needs after the women’s receipt of the genetic test result. In line
with the literature, we expect significant differences between women according to the genetic test
result received (positive, negative, or VUS) in terms of intensity [30,37,41] or hierarchy [39] of needs.
This report comprises a number of limitations. Our study samples mainly comprised BC patients;
therefore, the results may not reflect the psychosocial needs of healthy women that are at a high BC
genetic risk (e.g., female relatives) undergoing genetic counseling. Moreover, we assessed a limited
number of needs correlates, thus potentially missing out on other relevant needs. Further, so far, our
data is cross-sectional, i.e., no causal conclusions can be drawn. Hence, in order to provide more
specific clinical recommendations, further research should address additional factors in longitudinal
study designs. The impact of recent advances in BC risk genetic testing and counseling requires the
monitoring of counselees’ well-being. Future research should address the effects of different genetic
counseling delivery models, such as the risk communication style on counselees’ psychosocial needs.
Only two quantitative studies that addressed overall psychosocial needs were identified from the
literature review based on the chosen databases and keywords. In fact, the psychometric assessment
of needs happens to be a relatively new area of research in the cancer field [15]. In the genetic
counseling context, this outcome has hardly been considered [43–45]. The development of a standard
questionnaire to assess psychosocial needs in the cancer genetics population has only recently been
implemented [17].
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Among the seven studies selected, the population samples varied (i.e., in terms of hereditary
cancer syndromes, cancer diagnosis, gender, assessment timing), and so, beyond general observations
such as high needs prevalence regarding the cancer experience or in relation to younger age and
anxiety, making comparisons and drawing conclusions on more specific observations between studies
remain problematic.
Moreover, four different needs questionnaires were employed. Most of them assessed the
severity of difficulties, concerns or worries [38,40], and positive or negative emotions [39,41].
Only Farrelly et al. [36] used a questionnaire that directly assessed the presence and intensity of needs,
whereas only such an instrument can pinpoint the patient’s or counselee’s expectations with regard
to counseling. Furthermore, the data obtained from these different questionnaires were reported in
different ways (i.e., either item by item, or by domain or scale), and only one questionnaire (MICRA [16])
evidenced psychometric properties.
5. Conclusions
A high prevalence of psychosocial needs clustering around the personal and familial experience
of cancer, and the interpersonal aspects of hereditary cancer, were observed among women undergoing
BC genetic counseling in a cancer genetic clinic in France and Germany. An increased number of needs
were observed in younger, more anxious women, and in those having children, independently from the
country setting. This suggests that these younger women in particular may need additional counseling
during the course of BC genetic testing. Specific needs were also observed in each country clinic,
underlying the relevance of needs assessment in the clinical care setting. A literature review supported
these findings, and also pointed at future research directions with regards to BC genetic counseling
practices. We should move forward to provide standardized and valid instruments that allowing
unambiguous scoring and reporting of counselees’ psychosocial needs within and across cancer genetic
clinics. Moreover, in line with recent advances in cancer genetics and risk counseling, future research
should focus on the genetic service delivery examining different models of risk communication and
counseling that may influence psychosocial needs. Health care specialists, like physicians, nurses,
counselors, and psychologists who attend to women at high genetic risk of breast cancer should be
trained to identify and respond to their psychosocial needs. In this way the benefits expected from
new cancer genetics discoveries and technologies may also manifest in clinical genetics settings by
optimally responding to counselees’ needs and ensure a patient-centered care in that setting.
Supplementary Materials: The following are available online at www.mdpi.com/1660-4601/15/2/319/s1,
Table S1: Literature search and article selection, Table S2: Study characteristics, Table S3: Measure characteristics
as provided by the original developmental or psychometric study.
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